Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.40 |
| ▸ | JAK3 | P52333 | 9/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328995 | 0.84 | EGFR (0.41) | BTKJAK3EGFR | |
| SCHEMBL19596123 | 0.83 | EGFR (0.43) | BTKJAK3EGFRITKJAK1 | |
| SCHEMBL23221941 | 0.83 | EGFR (0.43) | BTKJAK3EGFRITKJAK1 | |
| SCHEMBL23328551 | 0.82 | TEAD1 (0.43) | BTKJAK3EGFR | |
| SCHEMBL7808253 | 0.81 | CYP4A11 (0.39) | — | |
| SCHEMBL26363882 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL20240578 | 0.79 | DPP4 (0.42) | BTKJAK3EGFRITKJAK1 | |
| SCHEMBL23328325 | 0.79 | FGFR1 (0.41) | BTKJAK3EGFRITKJAK1 | |
| SCHEMBL24492173 | 0.79 | BTK (0.40) | BTKJAK3EGFRITKJAK1 | |
| SCHEMBL24492438 | 0.79 | BTK (0.40) | BTKJAK3EGFRITKJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | BTK 318/4885JAK3 196/4885EGFR 43/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | BTK 319/4885JAK3 153/4885EGFR 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.